Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Saddic, Louis A ^a   Wirt, Stacey ^a   Vogel, Hannes ^b   Felsher, Dean W ^b   Sage, Julien ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CASPASE 3; CYTOKERATIN 19; KI 67 ANTIGEN; MYC PROTEIN; RETINOBLASTOMA PROTEIN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; POLYPLOIDY; TUMOR SUPPRESSOR GENE; AGING; ANIMAL; CELL CYCLE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; LIVER TUMOR; METABOLISM; MOUSE MUTANT; PATHOLOGY; PRECANCER; PROTEIN BINDING; SURVIVAL;

ANIMALIA; MUS;

AGING; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, MUTANT STRAINS; POLYPLOIDY; PRECANCEROUS CONDITIONS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 79955866426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019758     Document Type: Article

References (83)

1. Hanahan D, Weinberg RA, (2000) The Hallmarks of Cancer. Cell 100: 57-70.
2. Lund AH, van Lohuizen M, (2004) Epigenetics and cancer. Genes Dev 18: 2315-2335.
3. Weinberg RA, (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
4. Sherr CJ, McCormick F, (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
5. Deshpande A, Hinds PW, (2006) The retinoblastoma protein in osteoblast differentiation and osteosarcoma. Curr Mol Med 6: 809-817.
6. Skapek SX, Pan YR, Lee EY, (2006) Regulation of cell lineage specification by the retinoblastoma tumor suppressor. Oncogene 25: 5268-5276.
7. Khidr L, Chen PL, (2006) RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219.
8. Nguyen DX, McCance DJ, (2005) Role of the retinoblastoma tumor suppressor protein in cellular differentiation. J Cell Biochem 94: 870-879.
9. Thomas DM, Yang HS, Alexander K, Hinds PW, (2003) Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol Ther 2: 124-130.
10. Classon M, Harlow E, (2002) The retinoblastoma tumour suppressor in development and cancer. Nature Rev Cancer 2: 910-917.
11. Iavarone A, (2004) Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature 432: 1040-1045.
12. Zheng L, Flesken-Nikitin A, Chen PL, Lee WH, (2002) Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res 62: 2498-2502.
13. Zheng L, Lee WH, (2002) Retinoblastoma tumor suppressor and genome stability. Adv Cancer Res 85: 13-50.
14. Srinivasan SV, Mayhew CN, Schwemberger S, Zagorski W, Knudsen ES, (2007) RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. J Biol Chem 282: 23867-23877.
15. Hernando E, (2004) Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430: 797-802.
16. Knudsen ES, Sexton CR, Mayhew CN, (2006) Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med 6: 749-757.
17. Harrington EA, Bruce JL, Harlow E, Dyson N, (1998) pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 95: 11945-11950.
18. Burkhart DL, Sage J, (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682.
19. Knudsen ES, Knudsen KE, (2008) Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 8: 714-724.
20. Grandori C, Cowley SM, James LP, Eisenman RN, (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
21. Oster SK, Ho CS, Soucie EL, Penn LZ, (2002) The myc oncogene: MarvelouslY Complex. Adv Cancer Res 84: 81-154.
22. Pelengaris S, Khan M, Evan G, (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776.
23. Dang CV, (1999) c?Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11.
24. Pelengaris S, Khan M, Evan G, (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776.
25. Meyer N, Penn LZ, (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
26. Felsher DW, Bishop JM, (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 96: 3940-3944.
27. Caldwell S, Park SH, (2009) The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44 (Suppl 19): 96-101.
28. McMahon BJ, (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49: S45-55.
29. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
30. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, et al. (2010) Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005.
31. Sherman M, (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30: 3-16.
32. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, et al. (2004) Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol 2: e332.
33. Abou-Elella AGT, Fritsch C, Gansler T, (1996) c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Modern Pathology 9: 95-98.
34. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y, (1999) Amplification of c-Myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression. Oncology 57: 157-163.
35. Laurent-Puig P, Zucman-Rossi J, (2006) Genetics of hepatocellular tumors. Oncogene 25: 3778-3786.
36. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
37. Sandgren EPQC, Pinkert CA, Palmiter RD, Brinster RL, (1989) Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4: 715-724.
38. Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, et al. (2008) Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 68: 5132-5142.
39. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, et al. (2007) Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 104: 13028-13033.
40. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, et al. (2006) Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 103: 16266-16271.
41. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T, (2003) Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223-228.
42. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, et al. (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
43. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, et al. (1994) Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. Embo J 13: 4251-4259.
44. Mayhew CN, Bosco EE, Fox SR, Okaya T, Tarapore P, et al. (2005) Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res 65: 4568-4577.
45. Roskams T, (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822.
46. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, et al. (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461.
47. Conner EA, Lemmer ER, Sanchez A, Factor VM, Thorgeirsson SS, (2003) E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models. Biochem Biophys Res Commun 302: 114-120.
48. Machida K, Liu JC, McNamara G, Levine A, Duan L, et al. (2009) Hepatitis C Virus Causes Uncoupling of Mitotic Checkpoint and Chromosomal Polyploidy through the Rb Pathway. J Virol.
49. Srinivasan SV, Mayhew CN, Schwemberger S, Zagorski W, Knudsen ES, (2007) RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. J Biol Chem 282: 23867-23877.
50. Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, et al. (2007) RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133: 976-984.
51. Celton-Morizur S, Desdouets C, (2010) Polyploidization of liver cells. Adv Exp Med Biol 676: 123-135.
52. Ganem NJ, Storchova Z, Pellman D, (2007) Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 17: 157-162.
53. Murakami H, (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53: 1719-1723.
54. Sargent LM, (1999) Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-[alpha] in the liver. Am J Pathol 154: 1047-1055.
55. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS, (1998) Disruption of the pRb/E2F Pathway and Inhibition of Apoptosis Are Major Oncogenic Events in Liver Constitutively Expressing c-myc and Transforming Growth Factor alpha. Cancer Research 58: 123-134.
56. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS, (2004) Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 126: 1374-1386.
57. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, et al. (2009) Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 69: 2775-2782.
58. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
59. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM, (1997) Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8: 1039-1048.
60. Kim JW, Mori S, Nevins JR, (2010) Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 70: 4820-4828.
61. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J, (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20: 3497-3509.
62. Sears RC, Nevins JR, (2002) Signaling networks that link cell proliferation and cell fate. J Biol Chem 277: 11617-11620.
63. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, et al. (2009) Division and apoptosis of E2f-deficient retinal progenitors. Nature 462: 925-929.
64. Macpherson D, (2008) Insights from mouse models into human retinoblastoma. Cell Div 3: 9.
65. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, et al. (2003) Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 106: 334-341.
66. Knudsen ES, Knudsen KE, (2008) Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 8: 714-724.
67. Laurent-Puig P, Zucman-Rossi J, (2006) Genetics of hepatocellular tumors. Oncogene 25: 3778-3786.
68. Mayer RJ, Fujita J, (2006) Gankyrin, the 26 S proteasome, the cell cycle and cancer. Biochem Soc Trans 34: 746-748.
69. Hsieh YH, Su IJ, Wang HC, Tsai JH, Huang YJ, et al. (2007) Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res 5: 1063-1072.
70. Park SG, Chung C, Kang H, Kim JY, Jung G, (2006) Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem 281: 31770-31777.
71. Wang WH, Hullinger RL, Andrisani OM, (2008) Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem 283: 25455-25467.
72. Kim YJ, Jung JK, Lee SY, Jang KL, (2009) Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett.
73. McGivern DR, Lemon SM, (2009) Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 4: 399-415.
74. Ho VM, Schaffer BE, Karnezis AN, Park KS, Sage J, (2009) The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene.
75. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, et al. (2010) Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567-571.
76. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, et al. (2010) Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468: 572-575.
77. Manning AL, Longworth MS, Dyson NJ, (2010) Loss of pRB causes Centromere Dysfunction and Chromosomal Instability. Genes Dev.
78. Sage J, Straight AF, (2010) RB's original CIN? Genes Dev 24: 1329-1333.
79. Stadtfeld M, Hochedlinger K, (2010) Induced pluripotency: history, mechanisms, and applications. Genes Dev 24: 2239-2263.
80. van Harn T, Foijer F, van Vugt M, Banerjee R, Yang F, et al. (2010) Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev.
81. Cimini D, (2008) Merotelic kinetochore orientation, aneuploidy, and cancer. Biochim Biophys Acta 1786: 32-40.
82. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043-1047.
83. Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, et al. (2010) Regulation of RB transcription in vivo by RB family members. Mol Cell Biol 30: 1729-1745.